Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma - Wikidata - wikimedia - TriplyDB

Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma

Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma

http://www.wikidata.org/entity/Q28286125

about

Bortezomib for the treatment of mantle cell lymphoma: an update Metalloid compounds as drugs Role of T cell-nuclear factor κB in transplantation Corticospinal Motor Neurons Are Susceptible to Increased ER Stress and Display Profound Degeneration in the Absence of UCHL1 Function Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse Pathway analysis for drug repositioning based on public database mining Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome.Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.A whole-genome RNA interference screen for human cell factors affecting myxoma virus replication Expression and cellular distribution of ubiquitin in response to injury in the developing spinal cord of Monodelphis domestica.Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner Cell death signaling and anticancer therapy Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor.Transcriptional Activation of Pericentromeric Satellite Repeats and Disruption of Centromeric Clustering upon Proteasome Inhibition.Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy.Molecular pathways: turning proteasomal protein degradation into a unique treatment approach.An integrated network platform for contextual prioritization of drugs and pathways Bortezomib for the treatment of non-Hodgkin's lymphoma Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Targeting ubiquitination for cancer therapies.Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.Correlation of BAG-3 and heat shock protein 70 with CD30 expression in T-cell lymphomas.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges.Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma Synthesis and characterization of organic impurities in bortezomib anhydride produced by a convergent technology.ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2.Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.Temporally distinct transcriptional regulation of myocyte dedifferentiation and Myofiber growth during muscle regeneration.Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads.

P2860

Q26738940-C21D1EEF-AD16-4991-9F0C-93A0169C631E Q26822682-CCAB8E52-18FF-4C48-ADDF-66C785621096 Q26852416-24211A73-758A-42FE-80EC-297CA6B02CBD Q27302932-7EEED4FD-A630-4F42-9D03-9A9D352E8141 Q28085631-EBB962B7-8DE9-4806-809F-E56C05B84014 Q28533426-0F58F2D6-E020-494A-9E8D-F04E1DEC786A Q28657698-72AEF98B-C79C-472D-A81B-1C959F4432DA Q33601825-3322156B-C088-466B-A902-6E40D11E2677 Q33607221-067D3C1B-057F-45D0-9EFB-972DD9DB5B36 Q34384021-11C79E05-C381-4BD9-A776-62A5BE36FDAC Q34585582-5E6DCDCA-2C7E-4FA2-9672-357587AA53FD Q34692747-43ADFCE6-7A66-4D30-AB4F-9D564A40B00F Q35146262-0711E270-120C-47D3-B550-C29A80D6DAE6 Q35607281-7C70A0F6-B705-4D8B-A8C6-E3FBF50DB37F Q35620201-22AA776B-FA90-4B0D-B8D3-CB8B5DB53C7A Q35779961-2A4466AB-8763-4173-A660-59A6D59A9093 Q35972102-2CC1EB7A-DED6-4817-9DBF-340746583F1A Q35989980-F1111D2F-3663-45BC-AB84-C37D11A97E7F Q36037323-F6D5F03A-8AF4-4FB9-8FDF-54098A4BDB93 Q36139948-81ADFC6D-39CE-4E39-A5BC-F2E4081F95AB Q36180376-976646E2-FB44-4129-BCAA-320CFB0A762E Q36226588-B974B57C-3A2E-45AD-8467-6D87771FBDA6 Q36436413-ED9E5D31-4A8C-4809-A114-876E8B559297 Q36746321-727844AB-A0F4-47E0-95E0-3010CC22F56D Q36868056-03517DF6-71CF-4557-8942-885DCDF40877 Q37114025-A370179B-FDC5-4C88-95EF-3184B4A8634B Q37158445-FF346597-B44B-40E2-83E4-7869189CF6C5 Q37327294-450D5EFD-D0DF-481A-949B-AD78336B35A0 Q37440765-75A8454D-D6C7-4D4F-9FEF-8A190883F7CF Q37550446-EA95C7E7-4D08-4F3C-9232-DED400F5C075 Q38237657-B6ABEB94-5DAE-4926-9A11-77047883B1B0 Q38830422-A6E42FB1-52C9-4AB2-ABE5-7F8B833511B5 Q38976702-FA63C962-B85B-4B8F-BF2D-61CE0A893C50 Q39031250-B5D15E66-9FFC-45BD-BF33-AD08C066513D Q42094139-393E9F67-198E-4F2D-90D6-A71AA1B301ED Q42606592-3F1D3F76-934E-465A-B194-A358295BF7B3 Q42943366-BA0D1F0C-DDFD-4D3D-B1F7-5922C1DC59E0 Q45324502-29EDD340-9A84-4BAE-A2C3-FF964513C788 Q47103791-3603F593-CCE4-4AA2-ADD7-AA5DC3A2CAFA Q47145773-BE2C5C1E-9B8B-4578-8FDF-B37EDC0C097C

P2860

Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma

http://www.wikidata.org/entity/Q28286125

description

2007 nî lūn-bûn

@nan

2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@ast

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@en

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@nl

type

label

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@ast

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@en

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@nl

prefLabel

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@ast

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@en

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@nl

P1433

Q28286125-E56F937F-5557-4D72-AC44-DA11CFDD60CA

P1476

Q28286125-897E1F49-797D-4586-8B01-A5A4869C29AB

P2093

Q28286125-0BE79C0C-03E9-45E7-992D-DD894D37D3AD

Q28286125-702C8DB6-071D-4726-B287-5FD859ABCA69

Q28286125-71FAF5F3-8CBC-4D7D-AA29-5D515F2C26C8

Q28286125-9E2BE4B2-62A4-4DCB-9782-54000B1A7FC4

P2888

Q28286125-558B57A4-9251-40E7-90D4-B2D9931D232A

P304

Q28286125-F8798FB3-1C74-4C26-85F9-89D7EDC77380

P31

Q28286125-E6D25E48-3847-4C13-825D-6E1200B4C16B

P3181

Q28286125-92306F78-A65D-4ACD-94D2-A7FC837981A7

P356

Q28286125-DE7548A7-C497-4C18-8443-E86C1C6890E8

P407

Q28286125-97566B54-BD66-496A-A332-7B764494E546

P433

Q28286125-E121D75D-04DE-45FE-B9AE-A6F860ABCED1

P478

Q28286125-80E8B5E0-490E-472E-B764-81BFF376B89A

P577

Q28286125-3FEF231C-56B7-4EA6-9F91-90EB9A8916D1

P5875

Q28286125-BF273204-7BB2-4E8D-92B8-969FC31FC80D

P6179

Q28286125-2D90C296-9E8A-44FE-AB3C-D19A0D6A1BD5

P698

Q28286125-961BF44F-20A8-4FE7-99FD-C2D226CB8976

P3181

P356

P1433

P1476

Bortezomib-mediated 26S protea ...... anaplastic large cell lymphoma

@en

P2093

A Rosolen

http://www.w3.org/2001/XMLSchema#string

E Zorzi

http://www.w3.org/2001/XMLSchema#string

G Basso

http://www.w3.org/2001/XMLSchema#string

P Bonvini

http://www.w3.org/2001/XMLSchema#string

P2888

P304

838-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2696348

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.LEU.2404528

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6535192

http://www.w3.org/2001/XMLSchema#string

P6179

1032764842

http://www.w3.org/2001/XMLSchema#string

P698

17268529

http://www.w3.org/2001/XMLSchema#string